Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治仪治
,比较治
患者症状、体征、肝功能的变化。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治仪治
,比较治
患者症状、体征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈,而且是诸
慢性肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤仪
,比较
者症状、体征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈,而且是诸
慢性肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)者接受α干扰素包括派罗欣
存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超仪
,比较
前后患者症状、体征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能异常影响愈后,而且是诸
慢性肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣时存在肝功能失代
亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤仪
,比较
者症状、体征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈,而且是诸
慢性肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)者接受α干扰素包括派罗欣
存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝功能异常和影响愈后,而且是诸慢性肝病向肝硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、肝变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维化不仅造成慢性肝炎、肝常和影响愈后,而且是诸
慢性肝病向肝硬化发展
阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝
失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未过人工审核,其表达内容亦不代表本软件
观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患症状、体征、肝功能
。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
肝纤维不仅造成慢性肝炎、肝功能异常和影响愈后,而且是诸
慢性肝病向肝硬
发展
必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬慢性丙肝(CHC)患
α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、功能的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
纤维化不仅造成慢性
、
功能异常和影响愈后,而且是诸
慢性
病向
硬化发展的必经
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
并
硬化的慢性丙
(CHC)患者接受α干扰素包括派罗欣治疗时存在
功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Methods Symptoms, signs, liver function of the cases before and after ascites superfilter concentration and reinfusion treatment were compared.
方法采用腹水超滤治疗仪治疗,比较治疗前后患者症状、体征、的变化。
The fibrosis of liver not only causes chronic hepatitis, hypohepatia, and sequelae after cure, but also is the necessary process of hepatocirrhosis.
纤维化不仅造成慢性
炎、
异常和影响愈后,而且是诸
慢性
病向
硬化发展的必经阶段。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并硬化的慢性丙
(CHC)患者接受α
包括派罗欣治疗时存在
失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。